ARVO 2023: Insight into cell death with AMD

Article

Dr Deborah Ferrington talks about her ARVO presentation on using human donor tissue to identify the mechanism responsible for the death of the retinal pigment epithelium.

Dr Deborah Ferrington talks about her presentation on using human donor tissue to identify the mechanism responsible for the death of the retinal pigment epithelium.

Video transcript

Editor’s note: Transcript edited for clarity

Deborah Ferrington, PhD:

Good afternoon. My name is Deborah Ferrington, and I'm the Chief Scientific Officer at Doheny Eye Institute. I'm here at the ARVO meeting in New Orleans. And I gave a talk this morning on the cell death group. And what I talked about was our work using human donor tissue to identify the mechanism responsible for the death of the retinal pigment epithelium.

The group that we looked at were donors that had the complement factor, high-risk allele that is associated with AMD. We compared their results with donors that have the low-risk allele. What we found is that donors with high-risk for AMD, they had lower mitochondrial function and this lower mitochondrial function could be one of the things that tips the balance between a healthy donor's RPE and those that go into age-related macular degeneration.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
© 2024 MJH Life Sciences

All rights reserved.